Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease

Neurosci Lett. 2014 Mar 20:563:140-3. doi: 10.1016/j.neulet.2014.01.016. Epub 2014 Feb 2.

Abstract

Presenilin 1 (PSEN1) gene mutations are found in 30-70% of familial early-onset Alzheimer disease (EOAD) cases (onset <60 years). Prevalence of these mutations is highly variable including ethnic differences worldwide. No Peruvian kindred with familial AD (FAD) have been described. Standardized clinical evaluation and cognitive assessment were completed in a Peruvian family with severe EOAD. Clinical course was characterized by very early onset (before age 35 years), progressive cognitive impairment with early memory loss, spatial disorientation and executive dysfunction. We sequenced all exons of PSEN1 in the proband and identified a c.475C>G DNA change resulting in a p.L153V missense mutation in the transmembrane domain 2 of the gene. This mutation is also present in the three additional affected siblings but not in a non-affected family member consistent with segregation of this mutation with the disease. This is the first report of a Peruvian family affected with EOAD associated with a PSEN1 mutation. This same mutation has been reported previously in English and French families, but a novel variants very close to the mutation and ancestry informative markers analysis suggests the mutation might be of Amerindian or African origin in this Peruvian family.

Keywords: Early-onset Alzheimer's disease; Peruvian; Presenilin-1.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Age of Onset
  • Alzheimer Disease / ethnology
  • Alzheimer Disease / genetics*
  • Alzheimer Disease / physiopathology
  • Female
  • Humans
  • Male
  • Mutation, Missense
  • Pedigree
  • Presenilin-1 / genetics*

Substances

  • PSEN1 protein, human
  • Presenilin-1